India has taken advantage of the expiration of the patent for Ozempic, a popular drug used for weight loss and diabetes treatment, by launching generic versions that are significantly cheaper. Indian pharmaceutical company Natco Pharma Ltd. is planning to produce a semaglutide injection priced at around 1290 rupees (approximately $14) per month, aiming to provide affordable options in a country where the prevalence of overweight individuals is notably high.

The expected release date for Natco's pen device is in April, with an estimated monthly cost of about 4500 rupees. This is in stark contrast to the prices set by Novo Nordisk for its Wegovy pen, which starts at approximately 10,480 rupees in India and around $199 in the United States through direct payment methods. Other companies in India, such as Sun Pharmaceutical and Dr. Reddy’s Laboratories, are also marketing their semaglutide products at various price points, enhancing competition in the market.

The entry of these generics is poised to make treatment more accessible for many Indians suffering from obesity and diabetes, potentially reshaping the market dynamics for such medicines. As India has one of the largest populations with overweight individuals, this move could lead to significant public health improvements if these therapies become widely used and accepted. Overall, the launch of inexpensive generic options could challenge the domination of brand-name pharmaceuticals and promote greater health equity in the region.